Global pharma powerhouse Eli Lilly and Company has announced that the US FDA has approved has approved a new KwikPen for Zepbound (tirzepatide), letting patients get a full month of obesity treatment in a single, easy-to-use device.

The move gives patients and healthcare providers more flexibility in selecting the treatment option that best fits individual needs.

Patients with a valid prescription who choose self-pay through LillyDirect can now receive Zepbound in the KwikPen or single-dose vials, starting at $299 per month for the 2.5 mg dose.

"Zepbound is the #1 prescribed injectable obesity‑management medication, helping adults achieve meaningful and clinically proven weight loss, on average, up to 50 pounds as seen in SURMOUNT-5," said Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities.

"As part of our commitment to supporting people living with obesity in their weight management journey, we are introducing a new option with the Zepbound KwikPen, a device trusted by patients globally and in the United States for other Lilly medicines."

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect, which offers self-pay pricing at a 50% or greater discount compared to other incretin (GLP-1) obesity medicines. One in three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials, highlighting strong demand for the program.

"After trying so many times to lose weight over the years, I'm grateful I talked to my doctor about Zepbound," said Jacob M, Zepbound patient and LillyDirect customer. "Along with diet and exercise, Zepbound has helped me make real, lasting progress. And LillyDirect made getting the medicine simple, from filling my prescription to home delivery. I feel supported at every step of my weight loss journey."

The demand for Zepbound reflects its strong efficacy. In the SURMOUNT-1 trial, adults taking 15 mg of Zepbound lost an average of 20.9% of body weight over 72 weeks, compared to 3.1% with placebo. In the open-label SURMOUNT-5 study, participants lost an average of 50 lbs (20.2%), versus 33 lbs (13.7%) for those on injectable Wegovy.